Investors
Building the future of HRD cancer treatment
A first-in-class opportunity in precision oncology.
Investment highlights
- First-in-class mechanism targeting uracil excision
- Strong IP strategy and patent filings
- Backed by Institut Curie discoveries
- Addressing a major unmet need (PARPi resistance)
- Multi-billion € market potential
Market opportunity
HRD cancers represent a significant
and growing market across multiple indications:
- Ovarian cancer
- Breast cancer
- Prostate cancer
- Pancreatic cancer
Pipeline
- UNGi®
First-in-class UNG inhibitors targeting DNA repair vulnerability. - Urex®
Combination strategy enhancing uracil incorporation and therapeutic efficacy.
Development roadmap
- Preclinical validation (ongoing)
- Proof of concept in vivo
- Lead nomination
- IND / CTA submission
Funding
We are currently raising:
- €3M → proof of concept
- €11M → IND/CTA submission
